Jasreet Hundal

Abstract Glioblastoma is a fatal disease with a median prognosis of 12–18 months. Recent studies have shown encouraging results using neoantigen-based vaccines to stimulate glioblastoma-directed immune responses, but overall immunogenicity has been low.

Published April 14, 2025 | Version v1.3.0 Software Open # Workflows for Genomic Analysis A collection of WDL workflows for analysis of genomic sequencing data. These enable primary analysis of many common experiments, including somatic and germline variant calling, RNA sequencing, epigenomic assays, and ommunogenomics approaches for cancer vaccine development.

To create an individualized cancer vaccine, researchers must identify cancer-specific peptides called neoantigens, then use a cell-, protein-, or nucleic acid–based platform to deliver those neoantigens to patients to prime the immune system to attack the tumor. Next-generation sequencing data from tumor and normal DNA are aligned and compared to the human reference genome and then to each other to identify tumor-specific alterations.